The Stenting of Saphenous Vein Grafts (SOS) trial demonstrated a reduction in clinical and angiographic adverse events with paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS) in saphenous vein graft (SVG) lesions, but the rate of recurrent adverse events has not been described. METHODS: We performed a post hoc, landmark analysis to evaluate the risk of event recurrence following a non-fatal initial event among the SOS trial patients (pts). RESULTS: During a median follow-up of 35 months, the 80 pts enrolled in SOS experienced a total of 78 major cardiovascular events (MACE): 51 in the BMS group and 27 in PES group. No MACE were found in 28 pts (35) while 52 pts (65) had at least one event. The initial event was death in 13 pts (16). Among the 39 pts whose initial event was not fatal, 12 (31) had one or more subsequent MACE (50 of which were definitely related to the study SVG). The mean and median number of MACE per patient was significantly higher in patients receiving BMS versus PES (1.3 ± 1.2 and 1 ± 1.26 versus 0.6 ± 0.7 and 1 ± 0.825, p ≤ 0.005 and p ≤ 0.008, respectively). The rate of a second MACE following an initial event was 17 in the PES group and 37 in the BMS group (p ≤ 0.24). Ten of 12 pts with recurrent events had received a BMS (83). Conclusion: Pts undergoing SVG stenting had a high rate of recurrent events after an initial non-fatal event. These events were often related to the target vessel and most occurred in pts who had received a BMS, further supporting the benefit of PES over BMS in SVG lesions.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Invasive Cardiology|
|State||Published - Jun 1 2011|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine